東方鋯業(002167.SZ):擁有多個獨立的規模化生產基地
格隆匯5月15日丨東方鋯業(002167.SZ)在互動平台表示,公司是一家專注於鋯系列製品研發、生產和銷售的國家火炬計劃重點高新技術企業。公司擁有多個獨立的規模化生產基地,包括廣東汕頭、韶關樂昌、河南焦作以及雲南楚雄生產基地等。公司產品涵蓋氧氯化鋯、電熔鋯、二氧化鋯、複合氧化鋯、氧化鋯陶瓷結構件、硅酸鋯六大系列共一百多個品種規格,廣泛應用於電子陶瓷、生物陶瓷、結構陶瓷、色釉料、高温耐火材料、核能、新能源等行業,特別是在光伏、新能源電池材料、人造寶石、陶瓷基剎車片、種植牙及光通訊器件等領域擁有持續增長的市場佔有率。公司是目前國內鋯行業技術領先、規模居前、產業鏈條較為完整的高新技術企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.